TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03393819
Drug: DuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuraPrep surgical solution
Study: NCT00909155
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
Study: NCT00449644
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
Study: NCT00449644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
Study: NCT00349921
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
Study: NCT00349921
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance
Study: NCT00449644
Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
Study: NCT01212679
Drug: nomral saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
Study: NCT00018954
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00665054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets orally prior to sexual activity
Study: NCT00018954
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00724685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline
Study: NCT01660854
Drug: Malarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days: 4 tablets 250/100mg per day
Study: NCT00018954
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00018954
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01096368
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03070223
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
Study: NCT02305017
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 50 mg
Study: NCT01905228
Drug: CBL0137
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops
Study: NCT00753103
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
Study: NCT00753103
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily oral 1mg/kg tapered over 12 months
Study: NCT00753103
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
Study: NCT01202188
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match capsules for inhalation delivered via SDDPI.
Study: NCT01677598
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
Study: NCT03296137
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 doses (60 mg/kg) prior to TIL infusion
Study: NCT00089024
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
Study: NCT03608774
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
Study: NCT00089024
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
Study: NCT03608774
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
Study: NCT00752648
Drug: TMC435350
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02429557
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill given 1 hour before the second heat up tilt
Study: NCT04669262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match BGB-DXP593
Study: NCT04669262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match BGB-DXP604
Study: NCT01191645
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
Study: NCT02902302
Drug: Ibuprofen 400 mg/10 mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02902302
Drug: MOMENT 400 mg coated tablet
Normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03319953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-041 placebo-matching suspension
Study: NCT03319953
Drug: Second Generation Antipsychotics (SGA)
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
Study: NCT03524963
Drug: Cilostan CR Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostan CR Tab. 200mg once a day for 5 days
Study: NCT03524963
Drug: Pletaal SR Cap.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pletaal SR Cap. 200mg once a day for 5 days
Study: NCT00992199
Drug: cisplatin, Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
Study: NCT00771043
Drug: TYSABRI and AVONEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: TYSABRI and AVONEX treatment per package insert.
Study: NCT00098748
Drug: Optimized Background Therapy (OBT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBT (3-6 drugs based on treatment history and resistance testing)
Study: NCT00896337
Drug: Anti-platelet therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
Study: NCT01795495
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00360464
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03802344
Drug: MC2-01 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
Study: NCT03802344
Drug: Cal/BDP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
Study: NCT03802344
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream
Study: NCT01863173
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to control group
Study: NCT02220855
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03654170
Drug: BI 425809 mixed with [C-14] BI425809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT00585442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00790868
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg
Study: NCT01689025
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
Study: NCT06403306
Drug: Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
Study: NCT03518801
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active medication
Study: NCT01359254
Drug: Total Body Irradiation (TBI)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBI is given twice on the last day.
Study: NCT03423030
Drug: PBTZ169 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBTZ169 Formulation supplied as powder for oral solution
Study: NCT03423030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo supplied as powder for oral solution
Study: NCT03423030
Drug: PBTZ169 NCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBTZ169 NCP supplied as powder for oral solution
Study: NCT05240157
Drug: Corticosteroid Derivatives
Normalized name: Corticosteroid derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: observational
Study: NCT04159610
Drug: WO3970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT04159610
Drug: Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
Study: NCT03150966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take placebo in the form of capsules daily during 6 months study period
Study: NCT02058511
Drug: Anesthesia Premedication, Induction and Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain.
Study: NCT02348879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: contains no active drug
Study: NCT03907865
Drug: Softacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
Study: NCT02797665
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone 0.6mg/kg/d
Study: NCT00208936
Drug: Taxol, Cisplatin, 5-Fluorouracil, G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00464373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ml NaCl 0.9%
Study: NCT03821493
Drug: PF-06651600 10 mg tablets
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole.
Study: NCT01044745
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT00052611
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00308451
Drug: Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
Normalized name: biotin / chromium picolinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01892436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01941979
Drug: 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00886886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to MDMA or Reboxetine
Study: NCT00643786
Drug: Oxygène
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
Study: NCT01018134
Drug: Vehicle twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle topical spray administered to affected areas twice daily for 28 days
Study: NCT00559845
Drug: Epidoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
Study: NCT00559845
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
Study: NCT03438955
Drug: Omacor + Pritor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
Study: NCT03438955
Drug: Pritor + Omacor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
Study: NCT02242435
Drug: 4 mL Injection of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02450383
Drug: Acellular Dermal Matrix
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Study: NCT02557100
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00952445
Drug: T0903131 Besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT00952445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT00510718
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDV3100 daily until progression or dose-limiting toxicity
Study: NCT02513485
Drug: Levodopa+carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
Study: NCT02513485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Study: NCT02715882
Drug: CBLB502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02715882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04668950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will take 2 capsules per day as tolerated for approximately 15 days
Study: NCT01089439
Drug: Nitric oxide by inhalation INOMAX
Normalized name: nitric oxide / nitrogen Gas for Inhalation [INOmax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours
Study: NCT01089439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04675034
Drug: MEDI7352
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC injection of MEDI7352 as stated in arm description.
Study: NCT03018418
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
Study: NCT00362583
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00489424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00489424
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00489424
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01938508
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
Study: NCT01406938
Drug: AIN457 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1 injection per dose) and placebo to secukinumab 150 mg
Study: NCT01406938
Drug: AIN457 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 150 mg (2 injections per dose)
Study: NCT03855046
Drug: IncobotulinumtoxinA 50 U Intramuscular Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution.
Study: NCT02258971
Drug: BEA 2180 BR oral
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT02258971
Drug: BEA 2180 BR infusion
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion to be reconstituted with isotonic saline
Study: NCT03800524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months
Study: NCT02926027
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00638976
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
Study: NCT04590430
Drug: HFB30132A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
Study: NCT04779567
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 gr iv 4 times a day
Study: NCT04779567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml saline 0.9% iv 4 times a day
Study: NCT03487588
Drug: A-101 Topical Solution
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 Topical Solution applied Day 1, Day 15 and Day 29
Study: NCT02003638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo provided in the same pill quantity as niacin arm
Study: NCT00206128
Drug: Seroquel SR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02323126
Drug: EGF816
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF816 150 mg once daily (QD) administered orally as a capsule
Study: NCT02323126
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: INC280 400 mg twice daily (BID) administered orally as a tablet
Study: NCT00204594
Drug: rM28
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01058915
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5mg/day
Study: NCT01058915
Drug: Rosuvastatin 40mg
Normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40mg/day
Study: NCT00487942
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03520348
Drug: PRO-167
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic
Study: NCT05608395
Drug: 11C-Methionine PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)